U.S. stocks steady; Cook’s dismissal, Nvidia earnings in spotlight
In a recent transaction, Lish Scott, the Chief Operating Officer of Alphatec Holdings , Inc. (NASDAQ:ATEC), sold a significant portion of the company’s common stock. The medical device company, currently valued at $1.38 billion, has seen its stock decline 13% over the past week, though it maintains an impressive 81.57% gain over the last six months according to InvestingPro data. The sale, which took place on March 10, 2025, involved 27,994 shares, amounting to a total value of $272,101. The shares were sold at a weighted average price of $9.72 per share.
The sales were executed under a Rule 10b5-1 trading plan, initially adopted on December 14, 2022, and amended on August 10, 2023. This plan was designed to satisfy certain tax withholding obligations resulting from the vesting of restricted stock units. The transaction prices ranged from $9.45 to $10.35 per share.
Following this transaction, Scott retains ownership of 816,500 shares of Alphatec Holdings.
In other recent news, Alphatec Holdings reported its fourth-quarter 2024 earnings, revealing a revenue of $177 million, which surpassed analysts’ expectations of $170.35 million. However, the company missed its earnings per share (EPS) forecast, reporting -$0.23 compared to the expected -$0.05. Alphatec has also announced a private offering of $300 million in convertible senior notes due 2030, with an option for initial purchasers to acquire an additional $50 million. This move comes alongside a strategy to mitigate dilution through capped call transactions.
Additionally, Alphatec has issued $405 million in convertible notes and repurchased $253 million of its notes due 2026. The company plans to use proceeds from the new offering to fund capped call transactions and for general corporate purposes. Despite the earnings miss, TD Cowen has maintained its Buy rating for Alphatec with a target price of $22.50, citing the company’s solid revenue growth and positive cash flow outlook for 2025.
The company has set a revenue guidance of $732 million for 2025, indicating a projected 20% growth, with expectations of continued market share expansion in the spine market. These developments reflect Alphatec’s strategic financial maneuvers and its position within the medical technology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.